Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab can prolong remissions, conference told

Infliximab can prolong remissions in some of the most severe cases of Crohn's disease, researchers have reported.

News image

fiogf49gjkf04

A multi-center research team conducted the first large-scale trial of infliximab - also known as 'Remicade' - as maintenance therapy.

After 30 weeks of the study, patients receiving infusions of infliximab every 8 weeks were twice as likely to be in remission as those who were not receiving the drug.

The results of the trial, known as ACCENT-I, were revealed at the Digestive Disease Week meeting in Atlanta, United States.

Infliximab was approved by the Food and Drug Administration 3 years ago for short-term treatment of moderate to severe Crohn's disease and is the only non-steroidal medication indicated for the treatment of fistulas.

The study's director, Dr Stephen Hanauer, a Professor of Medicine at the University of Chicago, said it was the first therapy that truly allowed the disease to be managed over time.

"Ongoing treatment with infliximab decreased disease activity, prevented sudden attacks, and enabled patients to reduce - or, in many cases, completely eliminate - steroids," he commented.

Proportion of patients in remission at Week 30:
Placebo group: 21%
Infliximab, Group II: 39%
Infliximab, Group III: 45%
Digestive Disease Week

Almost 600 patients with moderate to severe Crohn's disease were involved in the study at 55 centers in North America, Europe, and Israel.

All patients received an initial dose of infliximab. The 335 patients (59%) who responded to the initial dose were randomized to one of 3 treatment groups.

All three groups received infusions at Weeks 2, 6, 14, 22, and 30 of the study. Group I received placebo (an infusion containing no medication), Group II received 5 mg/kg of infliximab, and Group III received 5 mg/kg of infliximab at Weeks 2 and 6, followed by 10 mg/kg at Weeks 14, 22, and 30.

By Week 30, patients in Groups II and III were twice as likely to be in remission as patients in Group I who received only the placebo.

Dr Hanauer said that almost 21% of the patients who received placebo had no symptoms at 30 weeks, but nearly 39% of those on the lower dose of infliximab, and 45% of those on the higher dose, were in complete remission.

He said infliximab also helped patients reduce their reliance on steroids; and patients reported higher quality-of-life scores at Week 30 than patients receiving the placebo.

"It would make a real difference for patients if we had alternatives to steroids, or better ways to reduce the steroid dose," said Hanauer.

However, infliximab has also been found to increase the risk of serious infection because it suppresses part of the immune response.

There are also reports of serious infusion reactions with hives, difficulty breathing, and low blood pressure, and in rare cases, people with de-myelinating disease who were treated with infliximab have seen their symptoms intensify.

Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com

Digestive Disease Week
23 May 2001

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us